SCOTTSDALE, Ariz., May 8, 2008 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced revenues for the three months ended March 31, 2008 of approximately $131.3 million, compared to approximately $95.1 million for the three months ended March 31, 2007, representing an increase of approximately 38%. This increase was primarily due to the strength of our acne product category, which includes SOLODYN(R), TRIAZ(R) and ZIANA(R). Medicis’ net income in accordance with U.S. generally accepted accounting principles (“GAAP”) for the three months ended March 31, 2008 was approximately $22.1 million, or approximately $0.34 per diluted share, compared to net income in accordance with GAAP of approximately $9.3 million, or approximately $0.15 per diluted share, for the three months ended March 31, 2007.
